These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 23647504)

  • 1. Fibrinolytic therapy of thrombosis in 27 newborns followed-up in neonatal intensive care unit.
    Aydın B; Beken S; Dilli D; Çınar HG; Özkan E; Zenciroğlu A; Okumus N
    Pediatr Hematol Oncol; 2013 Nov; 30(8):705-16. PubMed ID: 23647504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombolysis in newborns and infants.
    Nowak-Göttl U; Auberger K; Halimeh S; Junker R; Klinge J; Kreuz WD; Ries M; Schlegel N
    Thromb Haemost; 1999 Sep; 82 Suppl 1():112-6. PubMed ID: 10695499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Recombinant tissue plasminogen activator for the management of intracardiac thrombi in newborns].
    Álvarez Z P; Verdugo L P; Carvajal K L; Múhlhausen M G; Ríos A P; Rodríguez V D
    Rev Chil Pediatr; 2015; 86(3):194-9. PubMed ID: 26235268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Thrombolytic therapy using a low dose of tissue plasminogen activator in children].
    Santiago MJ; López-Herce J; Zarzoso S; Sánchez A; Mencía S; Carrillo A
    An Pediatr (Barc); 2012 Feb; 76(2):77-82. PubMed ID: 21982548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrinogen level as a surrogate for the outcome of thrombolytic therapy using tissue plasminogen activator for acute lower extremity intravascular thrombosis.
    Skeik N; Gits CC; Ehrenwald E; Cragg AH
    Vasc Endovascular Surg; 2013 Oct; 47(7):519-23. PubMed ID: 23899656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and outcomes of thrombolysis with tissue plasminogen activator for treatment of intravascular thrombosis in children.
    Gupta AA; Leaker M; Andrew M; Massicotte P; Liu L; Benson LN; McCrindle BW
    J Pediatr; 2001 Nov; 139(5):682-8. PubMed ID: 11713447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombolytic therapy in acute coronary thrombosis.
    Ramalanjaona GR; Mathew JC
    Indiana Med; 1990 Jun; 83(6):410-2. PubMed ID: 2112180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions.
    Sugimoto K; Hofmann LV; Razavi MK; Kee ST; Sze DY; Dake MD; Semba CP
    J Vasc Surg; 2003 Mar; 37(3):512-7. PubMed ID: 12618684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrinolytic profiles in local low-dose thrombolysis with streptokinase and recombinant tissue plasminogen activator.
    Berridge DC; Earnshaw JJ; Westby JC; Makin GS; Hopkinson BR
    Thromb Haemost; 1989 Apr; 61(2):275-8. PubMed ID: 2501898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the outcome of systemic tissue plasminogen activator for the management of venous and arterial thrombosis in pediatrics.
    Newall F; Browne M; Savoia H; Campbell J; Barnes C; Monagle P
    J Pediatr Hematol Oncol; 2007 Apr; 29(4):269-73. PubMed ID: 17414572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebral venous congestion as indication for thrombolytic treatment.
    Tsai FY; Kostanian V; Rivera M; Lee KW; Chen CC; Nguyen TH
    Cardiovasc Intervent Radiol; 2007; 30(4):675-87. PubMed ID: 17573553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic thrombolysis of portal vein thrombosis in cirrhotic patients: a pilot study.
    De Santis A; Moscatelli R; Catalano C; Iannetti A; Gigliotti F; Cristofari F; Trapani S; Attili AF
    Dig Liver Dis; 2010 Jun; 42(6):451-5. PubMed ID: 19819770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Thrombolytic treatment in acute myocardial infarction. Choice of preparations in Norwegian hospitals].
    Andreassen AK; Gullestad L; Endresen K
    Tidsskr Nor Laegeforen; 1998 Jun; 118(17):2630-1. PubMed ID: 9673511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of recombinant tissue plasminogen activator for venous thrombosis after paediatric heart surgery.
    Justice LB; Nelson DP; Palumbo J; Sawyer J; Patel MN; Byrnes JW
    Cardiol Young; 2018 Feb; 28(2):214-221. PubMed ID: 28889818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term benefit of one thrombolytic over another.
    Grobman BJ
    Circulation; 1997 Sep; 96(6):2093. PubMed ID: 9323115
    [No Abstract]   [Full Text] [Related]  

  • 16. [Thrombolytic therapy in acute myocardial infarct. New performance protocols. Their influence on mortality and the incidence of complications].
    Torres Martínez G; Rodríguez García P; Galcerá Tomás J; Castillo Soria F; Cantón Martínez A; Palazón Sánchez C; Seller Pérez G
    Rev Esp Cardiol; 1993 Apr; 46(4):235-41. PubMed ID: 8469808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of tissue plasminogen activator to treat intracardiac thrombosis in extremely low-birth-weight infants.
    Bose J; Clarke P
    Pediatr Crit Care Med; 2011 Nov; 12(6):e407-9. PubMed ID: 21131893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant tissue-type plasminogen activator therapy of thrombosis in 16 neonates.
    Farnoux C; Camard O; Pinquier D; Hurtaud-Roux MF; Sebag G; Schlegel N; Beaufils F
    J Pediatr; 1998 Jul; 133(1):137-40. PubMed ID: 9672527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Thrombolytic therapy of deep venous thrombosis. Indications, treatment procedures].
    Theiss W
    Internist (Berl); 1992 Apr; 33(4):225-31. PubMed ID: 1612846
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy of local instillation of recombinant tissue plasminogen activator for restoring occluded central venous catheters in neonates.
    Soylu H; Brandão LR; Lee KS
    J Pediatr; 2010 Feb; 156(2):197-201.e1. PubMed ID: 19969306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.